Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer
Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its drug candidate Alpha1H for the treatment of non-muscle invasive bladder cancer. The U.S. FDA Fast Track Designation...
Dela artikeln
Taggar: hamlet, biopharma, receives
Läs vidare på Dagens Industri